Results 121 to 130 of about 50,613 (304)

IS PSORIATIC ARTHRITIS REALLY PSORIATIC?

, 2014
The paper discusses the apparent rhetorical question whether psoriatic arthritis is psoriatic. Based on the data available in the literature and logical considerations, it has been suggested that accepted view may be contrary to ...
Sh. F. Erdes
core   +1 more source

Choosing the right treatment for patients with psoriatic arthritis

, 2020
Psoriatic arthritis (PsA) is a chronic inflammatory condition with articular and extra-articular manifestations: peripheral arthritis, axial disease, enthesitis, dactylitis, psoriasis, inflammatory bowel disease and uveitis. Anti-tumour necrosis factors (
Nash, P, Feletar, M, Noviani, M, Leung, YY   +3 more
core   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis.

, 2019
Importance It is necessary to determine whether psoriasis responds to methotrexate in the same manner in patients with and without psoriatic arthritis.
Li, Xueying, Wu, Mingshun, Han, Ling, Fang, Xu, Chang, Yuling, Xu, Qiaohu, Huang, Qiong, Qian, Danfeng, Yawalkar, Nikhil, Yan, Kexiang, Zhang, Yuanjing, Jin, Ling, Xu, Jinhua, Zhang, Zhenghua, Zhang, Qun, Zheng, Zhizhong, Zhang, Xuejun   +16 more
core   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

Magnetic resonance imaging of nail unit in psoriatic arthritis.

, 2009
The use of magnetic resonance imaging (MRI) has modified the imaging strategies of inflammatory arthritides. In psoriatic arthritis (PsA), MRI study of the nail unit identifies nail involvement that appears as the initial lesion for induction of distal ...
L. Costa, M. Atteno, S. Iervolino, DEL PUENTE, ANTONIO, M. A. Cimmino, F. Caso, E. Soscia, M. Salvatore, R. Scarpa, C. Sirignano, A. S.o.r.i.c.e.l.l.i., PELUSO, ROSARIO   +11 more
core   +1 more source

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

Clinical Pharmacology &Therapeutics, EarlyView.
Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu, Bella D. Ianni, Richard O. Day, Jacques Raubenheimer, Christine Y. Lu   +4 more
wiley   +1 more source

Psoriatic Arthritis Is an Indicator of Significant Renal Damage in Patients with Psoriasis: An Observational and Epidemiological Study

International Journal of Inflammation, 2017
Background. Psoriasis affects joints in around 30% of the patients. Recent studies have demonstrated an increased risk of essential hypertension, ischemic heart disease, and stroke in psoriatic patients.
Abidullah Khan, Iqbal Haider, Maimoona Ayub, Mohammad Humayun   +3 more
doaj   +1 more source

S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis

, 2016
Objective: To evaluate levels of the calcium-binding proteins S100A8 and S100A9 in the skin of patients with psoriatic arthritis. Methods: Skin punch biopsies were obtained from patients with psoriatic arthritis and healthy control subjects.
Conigliaro, Paola, Maria Sole Chimenti, Paola Conigliaro, Costanzo, A, Triggianese, Paola, Conigliaro, P, Perricone, R, Giunta, Alessandro, Roberto Perricone, Botti, E, Costanzo, Antonio, Giunta, A, Costanzo, A., Antonio Costanzo, NARCISI, ALESSANDRA, Chimenti, MS, Teoli, Miriam, Triggianese, P, Elisabetta Botti, Alessandro Giunta, BOTTI, ELISABETTA, Alessandra Narcisi, Chimenti, Maria Sole, Perricone, Roberto, Paola Triggianese, Teoli, M, Narcisi, A, Miriam Teoli   +27 more
core   +1 more source

Inhibition of interleukins 17A and 17F in psoriatic arthritis

, 2020
Psoriasis is the most common chronic inflammatory skin disease; 15–30% of patients with psoriasis have psoriatic arthritis.1 The interleukin (IL) 23 and IL17 pathway has a crucial role in pathogenesis, and inhibitors of the IL17 pathway have rewritten ...
Nash, P, Nash, Peter
core   +1 more source